NDA 216354 · Teva
Austedo Xr
Deutetrabenazine · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Feb 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Feb 17, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
18
11 Phase 3, 2 recruiting
FAERS reports
2,016
1,213 serious, 159 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DEPRESSION AND SUICIDALITY IN PATIENTS WITH HUNTINGTON’S DISEASE AUSTEDO XR and AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntington’s disease. Anyone considering the use of AUSTEDO XR or AUSTEDO must balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Patients, their caregivers, and families should be informed of the risk of depression and suicidality and should be instructed to report behaviors of concern promptly to the treating physician. Particular caution should be exercised in treating patients with a history of depression or prior suicide attempts or ideation, which are increased in frequency in Huntington’s disease. AUSTEDO XR and AUSTEDO are...
What it is approved for
From the label in effect Feb 28, 2025.
AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 14.1 )] tardive dyskinesia [see Clinical Studies ( 14.2 )] AUSTEDO XR and AUSTEDO are vesicular monoamine transporter 2 (VMAT2) inhibitors indicated in adults for the treatment of: Chorea associated with Huntington’s disease ( 1 ) Tardive dyskinesia ( 1 )
Mechanism: The precise mechanism by which deutetrabenazine exerts its effects in the treatment of tardive dyskinesia and chorea in patients with Huntington’s disease is unknown but is believed to be related to its effect as a reversible depletor of monoamines (such as dopamine, serotonin, norepinephrine, and histamine) from nerve terminals. The major circulating metabolites (α-dihydrotetrabenazine [HTBZ] and β-HTBZ) of deutetrabenazine, are reversible inhibitors of VMAT2, resulting in decreased uptake of monoamines into synaptic vesicles and depletion of monoamine stores.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
8 products under this application
- AUSTEDO XR · DEUTETRABENAZINE 12MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- AUSTEDO XR · DEUTETRABENAZINE 48MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- AUSTEDO XR · DEUTETRABENAZINE 36MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- AUSTEDO XR · DEUTETRABENAZINE 24MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- AUSTEDO XR · DEUTETRABENAZINE 6MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- AUSTEDO XR · DEUTETRABENAZINE 18MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- AUSTEDO XR · DEUTETRABENAZINE 42MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
- AUSTEDO XR · DEUTETRABENAZINE 30MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Deutetrabenazine" as an intervention, any sponsor and status, largest first.
- Reducing Involuntary Movements in Participants With Tardive DyskinesiaPivotal-lookingCompleted
Auspex Pharmaceuticals, Inc.Industry
NCT02198794 · 343 participants · Start Oct 20, 2014 · Primary completion Dec 6, 2019
Drug: SD-809; Placebo · For: Tardive Dyskinesia
Sites: Tuscaloosa, Alabama; Anaheim, California; Glendale, California · 82 sites in all
- Addressing Involuntary Movements in Tardive DyskinesiaPivotal-lookingCompleted
Auspex Pharmaceuticals, Inc.Industry
NCT02291861 · 298 participants · Start Oct 31, 2014 · Primary completion Aug 19, 2016
Drug: SD-809; Placebo · For: Tardive Dyskinesia
Sites: Tuscaloosa, Alabama; Anaheim, California; Glendale, California · 106 sites in all
- Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and AdolescentsPivotal-lookingTerminated
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT03567291 · 228 participants · Start May 25, 2018 · Primary completion May 15, 2020
Drug: TEV-50717; Placebo · For: Tourette Syndrome
Sites: Dothan, Alabama; Rogers, Arkansas; Anaheim, California · 76 sites in all
- A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)Pivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT03571256 · 158 participants · Start May 31, 2018 · Primary completion Dec 9, 2019
Drug: TEV-50717; Placebo · For: Tourette Syndrome
Sites: Gainesville, Florida; Gulf Breeze, Florida; Miami, Florida · 56 sites in all
- Alternatives for Reducing Tics in Tourette Syndrome (TS): A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and AdolescentsPivotal-lookingCompleted
Teva Branded Pharmaceutical Products R&D, Inc.Teva (TEVA)
NCT03452943 · 119 participants · Start Feb 5, 2018 · Primary completion Nov 12, 2019
Drug: TEV-50717; Placebo · For: Tourette Syndrome
Sites: Dothan, Alabama; Sun City, Arizona; Rogers, Arkansas · 42 sites in all
- Alternatives for Reducing Chorea in Huntington DiseasePivotal-lookingCompleted
Auspex Pharmaceuticals, Inc.Industry
NCT01897896 · 119 participants · Start Nov 12, 2013 · Primary completion Aug 21, 2017
Drug: SD-809 · For: Chorea Associated With Huntington Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Fayetteville, Arkansas · 38 sites in all
- Aim to Reduce Movements in Tardive DyskinesiaPivotal-lookingCompleted
Auspex Pharmaceuticals, Inc.Industry
NCT02195700 · 117 participants · Start Jun 2014 · Primary completion May 2015
Drug: SD-809; Placebo · For: Tardive Dyskinesia
Sites: Tuscaloosa, Alabama; Anaheim, California; Glendale, California · 41 sites in all
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
NCT07105111 · 100 participants (planned) · Start Aug 29, 2025 · Primary completion Jun 2028
Drug: Valbenazine · For: Schizophrenia; Schizoaffective Disorder; Bipolar Disorder and 2 more
Sites: Bryant, Arkansas; Chino, California; Fresno, California · 19 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective320
- depression183
- product use issue176
- dyskinesia156
- somnolence146
- fatigue136
- death131
- product use in unapproved indication131
- suicidal ideation119
- tremor118
- fall115
- tardive dyskinesia113
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 8 |
| 2020 | 4 |
| 2021 | 4 |
| 2022 | 15 |
| 2023 | 59 |
| 2024 | 485 |
| 2025 | 734 |
| 2026 | 701 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Austedo XR (Deutetrabenazine)
2024 spending
$597M
Beneficiaries
11,299
81,595 claims
Per beneficiary
$52,850
$224.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $90,977,519 |
| 2024 | $597,150,053 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment Recommendations for Tardive Dyskinesia.
Ricciardi L, Pringsheim T, Barnes TRE, et al. · Can J Psychiatry 2019 · Systematic Review
- The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, et al. · CNS Drugs 2022 · Multicenter Study, Randomized Controlled Trial
- Efficacy and safety of different pharmacological interventions in the treatment of tardive dyskinesia: a systematic review and network meta-analysis.
Ismail O, Albdour K, Jaber Y, et al. · Eur J Clin Pharmacol 2024 · Systematic Review, Network Meta-Analysis
- Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.
Bhidayasiri R, Jitkritsadakul O, Friedman JH, et al. · J Neurol Sci 2018 · Research Support, Non-U.S. Gov't, Systematic Review
- Efficacy and acceptability of pharmacological interventions for tardive dyskinesia in people with schizophrenia or mood disorders: a systematic review and network meta-analysis.
Solmi M, Fornaro M, Caiolo S, et al. · Mol Psychiatry 2025 · Systematic Review, Network Meta-Analysis
- Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis.
Connolly A, Wallman P, Dzahini O, et al. · Psychopharmacology (Berl) 2024 · Meta-Analysis, Systematic Review
Sponsor: Teva
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.